BioSight
Back
BIOCRYST PHARMACEUTICALS INC logo

BCRX

NASDAQDURHAM, NC
BIOCRYST PHARMACEUTICALS INC

BioCryst Pharmaceuticals develops small-molecule drugs targeting rare diseases, with a focus on complement system disorders and other inflammatory conditions. The company has ORLADEYO (berotralstat) approved and commercialized in the United States for hereditary angioedema, and maintains a pipeline of clinical and preclinical candidates including navenibart, BCX17725, avoralstat, and STAR-0310, along with discovery programs. BioCryst also partners with international companies like Torii and Shionogi for ex-U.S. development and commercialization of its products.

Price history not yet available for BCRX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.